Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

The U.S. Food and Drug Administration approved twice-daily JOURNAVX for the treatment of adults with moderate-to-severe acute pain. Vertex has established a wholesale acquisition ... APOL1-mediated ...

On Thursday, the digital media company's founder and CEO, Dave Portnoy, took to X to announce the sad news that Iga Obrycka, who was the general manager of Barstool Nashville, had passed away.

IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global ...

cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain ? and continues to advance clinical and research ... APOL1-mediated kidney disease, IgA nephropathy, primary ...

Acute renal failure is caused by damage to the kidneys, which can occur as a result of blood loss, toxins, or physical damage to the kidneys. Acute renal failure occurs rapidly, causing generalized ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and ...